Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951744 | 0.81 | MAPT (0.65) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30946935 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27986152 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30388558 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17600557 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6859623 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL710469 | 0.78 | ALDH1A1 (0.66) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15516428 | 0.76 | CYP1A2 (0.55) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13541765 | 0.76 | ALDH1A1 (0.55) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL670646 | 0.74 | CYP1A2 (0.62) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957496-B1 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARM INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-7648987-B2 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1979353-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2007084667-A2 | FUSED HETEROBICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICAL, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | CDK1, MAP4K2, MAP4K3 | ALDH1A1 4394/4885MAPT 1073/4885MEN1 3593/4885 |
| US-20070208053-A1 | Fused heterobicyclic kinase inhibitors | MAP2K5, MAP2K7, MAP2K2 | ALDH1A1 4769/4885MAPT 3449/4885MEN1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.